Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Zachary Lamkin

Podiatrist, Foot Surgery Texarkana, TX Doctor of Podiatric Medicine

NPI 1538643697 CMS profile 5404900

5606 Summerhill Rd, Texarkana, TX 75503

Open in the dashboard

General payments

$8,755

194 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Zachary Lamkin of Texarkana, TX is reported in the CMS Open Payments database as having received $8,755 across 194 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Podiatrist, Foot Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $472 18
2024 General $1,084 35
2023 General $1,244 40
2022 General $2,440 35
2021 General $2,044 21
2020 General $529 15
2019 General $943 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Zachary Lamkin
  • Podiatrist, Foot Surgery median
  • Middle half of Podiatrist, Foot Surgery
  • National median

In program year 2025, general payments to Zachary Lamkin were reported at $472. Among 732 Podiatrist, Foot Surgery profiles paid that year, the median was $180 and the middle half received between $70 and $569.

Show as a table
Year Zachary Lamkin Podiatrist, Foot Surgery median Middle half National median
2019 $943 $167 $67–$484 $163
2020 $529 $114 $40–$323 $114
2021 $2,044 $171 $57–$502 $132
2022 $2,440 $196 $66–$556 $149
2023 $1,244 $187 $78–$466 $160
2024 $1,084 $190 $78–$557 $164
2025 $472 $180 $70–$569 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $3,391 89 payments
  2. Alon Medical Technology $2,422 3 payments
  3. Organogenesis Inc. $670 20 payments
  4. Nevro Corp. $248 7 payments
  5. Smith+Nephew, Inc. $166 10 payments
  6. Zimmer Biomet Holdings, Inc. $148 2 payments
  7. Trilliant Surgical LLC. $132 1 payment
  8. Medline Industries, Inc. $124 1 payment
  9. Crossroads Extremity Systems, LLC $110 1 payment
  10. Ortho Solutions Inc $109 1 payment
  11. Other $1,236 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,355 192 payments
  2. Education $2,400 2 payments
Products named General payments · program years 2019–2025
  1. ANCHORAGE Trauma & Extremeties $613 9 payments
  2. ANCHORAGE Trauma & Extremeties $555 17 payments
  3. Puraply $422 14 payments
  4. ORTHOLOC 2 LAPIFUSE $420 12 payments
  5. AUGMENT INJECTABLE $322 7 payments
  6. ASNIS $319 8 payments
  7. Senza $248 7 payments
  8. Leqembi $139 6 payments
  9. ALLOGRAFT BIO-IMPLANTS $133 4 payments
  10. MIB $132 1 payment
  11. Other $2,887 110 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

625

Median for Podiatry: 160

Drug cost

$5,870

Median for Podiatry: $2,368

Branded share of claims

21.1%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciclopirox Ciclopirox Olamine Brand 120 $1,250
Diclofenac Sodium Generic 32 $1,005
Ammonium Lactate Generic 34 $1,002
Ciclopirox Generic 22 $800
Mupirocin Generic 89 $636
Meloxicam Generic 214 $476
Methylprednisolone Generic 29 $209
Gabapentin Generic 28 $162
Cephalexin Generic 23 $128
Terbinafine Hcl Generic 22 $125

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$41,770

Of which drugs: $30

Medicare patients

245

Average age 75

Services billed

890

147 women, 98 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 43%
Depression 34%
Ischemic heart disease 32%
Chronic kidney disease 27%
Atrial fibrillation 22%
Alzheimer's or dementia 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 11 32 $25
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 11 58 $5

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYEPTI
  • Lundbeck LLC $50
$50 — —
Bimzelx
  • UCB, Inc. $44
$44 — —
Qutenza
  • Averitas Pharma Inc. $41
$41 — —
TREMFYA
  • Janssen Biotech, Inc. $20
$20 — —
LUPKYNIS
  • Aurinia Pharma U.S., Inc. $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

194 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record